

OSTEOPORE EXPANDS FURTHER INTO EUROPE WITH INITIAL SALES TO SPAIN

Highlights:

- *Osteopore expands its footprint in Europe with the first shipment of its cranial regenerative implants to Spain.*
- *The initial sales represent an endorsement of Osteopore's continued strategy to penetrate new markets and drive uptake amongst surgeons.*
- *This milestone follows Osteopore's recent expansion into Latin America, with initial sales of its cranial regenerative implants to Colombia.*
- *Additional sales across Europe are expected to continue due to the diminishing COVID restrictions and increased recognition of the value propositions of Osteopore's innovative regenerative implants.*

14 April 2022: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale, is pleased to announce it has successfully expanded further into the European market with its first shipment of cranial (skull) regenerative implants to Spain.

The initial orders were received from Osteopore's Spain based distribution partner, Acuña y Fombona S.A, who have more than 50 years of industry experience and are one of the main distributors of medical and surgical materials in the region. The group also has extensive networks in various key cities regionally, such as Madrid, Barcelona, Valencia, Seville, and Salamanca, with headquarters in Gijón.


The initial shipment of Osteopore products will provide Acuña y Fombona S.A with sufficient inventory to engage their established network of health professionals, hospitals and health services, as well as support the sales team to successfully initiate clinical usage in the Spanish market.

The Spanish cranial procedures available to Osteopore products is estimated to be about 40,000 cases¹ per year, and while the initial Spanish sales are not material in terms of revenue, its significance represent an endorsement of Osteopore's continued strategy to penetrate new markets and drive uptake amongst surgeons.

Osteopore Executive Chairman, Mark Leong said, "Achieving first sales in Spain is yet another fantastic milestone for the company and displays our team's ability to execute on our strategy

to penetrate new markets. These initial sales are a clear example of the immediate commercial opportunity for Osteopore’s innovative regenerative implants. We are moving rapidly to regain momentum and have a fully dedicated sales team ready to take advantage of a significant backlog of elective surgeries from increased recognition of our superior products as well as better post COVID market access.”

Acuña y Fombona S.A. General Manager, Sergio López-Fombona, said, “We are excited to work with Osteopore to bring their Regenerative Implant for Craniofacial applications to Spain. This will allow us to expand our product portfolio with an outstanding technology and serve a wider range of needs across our network of surgeons and ultimately to give a better treatment opportunity to their patients.”




Global expansion regaining momentum

Osteopore’s craniofacial implants are superior, off-the-shelf products that are manufactured at scale and are indicated for used in over 1.1m craniofacial procedures globally¹. The implants resorb over time to leave behind only natural healthy bone, and have largely outperformed traditional implants in terms of design, ease-of-use and post-operative complications.

As the effects of COVID-19 begin to diminish across the world, Osteopore is experiencing increased engagement with hospitals, surgeons, and healthcare decision makers. These encouraging tailwinds are opening up opportunities to gain deeper and wider market adoption, and allow the Company to continue its vision to become the standard of care for bone and tissue regeneration globally.

With regulatory clearances and distribution partners secured in many major markets, the Company is rapidly moving towards growing its footprint across more regions where immediate commercial opportunities exist. A complementary pipeline of new products are also being developed for additional bone regeneration applications.

¹ Cetas Healthcare (2020). Market research conducted for Osteopore on the global cranial procedure market.



Osteopore has distribution partners and regulatory clearances in many major markets.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

About Acuña y Fombona S.A.

Acuña y Fombona S.A. is a Spanish distributor company with over 50 years of experience across various specialties, such as spine, craniofacial, maxillofacial, trauma & orthopaedic surgery, thoracic surgery, paediatric and paediatric orthopaedic surgery and more. Acuña y Fombona S.A has an extensive network of healthcare professionals and sales team across the whole territory of Spain and Portugal, with direct business offices in various key cities in Spain

and Portugal, including Madrid, Barcelona, Lisbon, Valencia, Porto, Salamanca, Seville and the headquarters in the foundational city, Gijón.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.